Felzartamab and Antibody-Mediated Rejection in Kidney Transplants — Hope at Last?

Many patients with transplanted kidneys ultimately lose them because of antibody-mediated rejection, yet approved therapies are lacking. Multiple mechanisms appear to be involved, beginning with donor-specific, antibody-dependent and -independent processes that can trigger the activation of natural killer (NK) cells, which leads to subsequent inflammatory and complement-mediated reactions.1 …

​   The New England Journal of Medicine: Search Results in Allergy/Immunology